Human
immunodeficiency virus (HIV) fusion inhibitors is the new class of antiretroviral
drugs for the treatment of HIV infections. Failure of combination
antiretroviral therapy in patients with HIV, has increased the risk of disease
progression. This has led to the development of next generation of fusion inhibitor
peptides for better treatment of HIV. Thus, fusion inhibitors have emerged as
attractive therapeutics for the treatment of HIV infections.
Request
to Get the Sample Pages at: https://www.pharmaproff.com/request-sample/1202
Studies
suggested that HIV fusion inhibitors offers potent antiretroviral activity but
its uptake has been limited because of the need for delivery by subcutaneous
injection administered twice-daily. Also, chances of cytotoxicity are low in
treatment with HIV fusion inhibitors therapeutics as they do not actually enter
the cells. Thus, providing many opportunities to the companies for the
development of new HIV fusion inhibitors with more potent activity and longer
half-lives for better therapeutics with reduced adverse events.
Report Description: https://www.pharmaproff.com/report/hiv-fusion-inhibitors
Frontier
Biotechnologies Inc. is in the process of developing Albuvirtide as a treatment-paradigm
shifting long-acting HIV fusion inhibitor for treatment of HIV infection. Mapp
Biopharmaceutical Inc., and United Biomedical Inc. are some other companies
having pipeline of HIV fusion inhibitors.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with detailed analysis of
pipeline and clinical trials. Pipeline analysis of drugs by phases includes
product description and development activities including information about
clinical results, designations, collaborations, licencing, grants, technology
and others.
